Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Amplia Therapeutics ( (AU:ATX) ).
Amplia Therapeutics has announced that the US Patent Office has allowed a key patent for its FAK inhibitor, narmafotinib, with a formal grant expected soon. This patent, already granted in several countries, extends narmafotinib’s protection until at least 2040, enhancing its commercial value. The patent describes a stable form of narmafotinib, which is being used in clinical trials for advanced pancreatic cancer, showing promising results. This development strengthens Amplia’s intellectual property portfolio and positions the company favorably in the pharmaceutical industry, particularly in the field of cancer treatment.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for treating cancer and fibrosis. The company targets fibrotic cancers such as pancreatic and ovarian cancer, and FAK plays a significant role in chronic diseases like idiopathic pulmonary fibrosis.
Average Trading Volume: 4,815,716
Technical Sentiment Signal: Hold
Current Market Cap: A$76.96M
See more data about ATX stock on TipRanks’ Stock Analysis page.